Physician profile
Mitchell Jv Maier
NPI 1306844154
$1,273.40
in general payments reported to CMS, 2019-2025
10 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $79.44 · 2021: $142 · 2022: $140 · 2023: $256 · 2024: $250 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $333.35 | 2019-2022 | |
| Alcon Vision LLC | $303.75 | 2019-2025 | Rhopressa, Rocklatan, Simbrinza |
| Johnson & Johnson Surgical Vision, INC. | $139.60 | 2019 | |
| Abbvie INC. | $139.36 | 2023-2025 | |
| Astellas Pharma US INC | $124.99 | 2024 | Izervay |
| Bausch & Lomb Americas INC. | $113.73 | 2023-2025 | Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $59.48 | 2019-2021 | |
| Biotissue Holdings INC. | $23.42 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.85 | 2022 | |
| Allergan, INC. | $16.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$10,335.19 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Maier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.